John Militello - Net Worth and Insider Trading
John Militello Net Worth
The estimated net worth of John Militello is at least $831,790 dollars as of 2024-11-05. John Militello is the See Remarks of Rocket Pharmaceuticals Inc and owns about 50,534 shares of Rocket Pharmaceuticals Inc (RCKT) stock worth over $831,790. Details can be seen in John Militello's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John Militello has not made any transactions after 2024-10-31 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of John Militello
John Militello Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John Militello owns 2 companies in total, including Rocket Pharmaceuticals Inc (RCKT) , and Immune Pharmaceuticals Inc (IMNPQ) .
Click here to see the complete history of John Militello’s form 4 insider trades.
Insider Ownership Summary of John Militello
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RCKT | Rocket Pharmaceuticals Inc | 2024-08-16 | See Remarks |
| IMNPQ | Immune Pharmaceuticals Inc | 2016-06-01 | See Remarks |
John Militello Latest Holdings Summary
John Militello currently owns a total of 1 stock. John Militello owns 50,534 shares of Rocket Pharmaceuticals Inc (RCKT) as of October 31, 2024, with a value of $831,790.
Latest Holdings of John Militello
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RCKT | Rocket Pharmaceuticals Inc | 2024-10-31 | 50,534 | 16.46 | 831,790 |
Holding Weightings of John Militello
John Militello Form 4 Trading Tracker
According to the SEC Form 4 filings, John Militello has made a total of 15 transactions in Rocket Pharmaceuticals Inc (RCKT) over the past 5 years, including 0 buys and 15 sells. The most-recent trade in Rocket Pharmaceuticals Inc is the sale of 917 shares on October 31, 2024, which brought John Militello around $15,250.
Insider Trading History of John Militello
- 1
John Militello Trading Performance
John Militello Ownership Network
Ownership Network List of John Militello
Ownership Network Relation of John Militello
John Militello Owned Company Details
What does Rocket Pharmaceuticals Inc do?
Who are the key executives at Rocket Pharmaceuticals Inc?
John Militello is the See Remarks of Rocket Pharmaceuticals Inc. Other key executives at Rocket Pharmaceuticals Inc include Chief Medical Officer Mark Andrew White , General Counsel Martin Wilson , and director & See Remarks Gaurav Shah .
Rocket Pharmaceuticals Inc (RCKT) Insider Trades Summary
Over the past 18 months, John Militello made 12 insider transaction in Rocket Pharmaceuticals Inc (RCKT) with a net sale of 22,492. Other recent insider transactions involving Rocket Pharmaceuticals Inc (RCKT) include a net sale of 48,601 shares made by Gaurav Shah , a net sale of 582,989 shares made by Gotham Makker , and a net sale of 16,701 shares made by Kinnari Patel .
In summary, during the past 3 months, insiders sold 19,727 shares of Rocket Pharmaceuticals Inc (RCKT) in total and bought 0 shares, with a net sale of 19,727 shares. During the past 18 months, 779,172 shares of Rocket Pharmaceuticals Inc (RCKT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 779,172 shares.
Rocket Pharmaceuticals Inc (RCKT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Rocket Pharmaceuticals Inc Insider Transactions
John Militello Mailing Address
Above is the net worth, insider trading, and ownership report for John Militello. You might contact John Militello via mailing address: C/o Immune Pharmaceuticals Inc., 430 East 29th Street, Suite 940, New York Ny 10016.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
